Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Q: When is the deadline for Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)?

This is a forecast opportunity; the agency expects applications to close June 4, 2027.

Q: Who is eligible for Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)?

Eligible applicants: For-profit businesses; City & township governments; Tribal organizations; Tribal governments; County governments; School districts; Public colleges & universities; Nonprofits (501(c)(3)).

National Institutes of Health

Federal

Funding Amount

Up to $150K

Deadline

Forecast — expected June 4, 2027

Forecast by the agency; not yet open

Number of Awards

Grant Type

Federal

Deadline history & next window

Cycle: Not stated
Next expected: June 4, 2027
Tracked since: September 2026

Forecast: expected to post January 15, 2027; applications expected due June 4, 2027.

Source: Grants.gov forecast for this opportunity.

Can we apply?

Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.

Eligible organizations

For-profit businesses
City & township governments
Tribal organizations
Tribal governments
County governments
School districts
Public colleges & universities
Nonprofits (501(c)(3))

Geography

Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Overview

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies for cancer research or clinical care. The emphasis of this NOFO is on early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument.

Well-suited applications must offer a high degree of technical innovation and the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Full eligibility text

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Focus Areas & Funding Uses

Fields of Work

Health

Draft your narrative and assess your fit in the Grantable app.

Start writing